Treatment of inflammatory bowel disease

Patent metadata

Field	Value
Publication number	US-9637467-B2
Application number	US-201514846016-A
Country	US
Kind code	B2
Filing date	Sep 4, 2015
Priority date	Feb 11, 2003
Publication date	May 2, 2017
Grant date	May 2, 2017

Abstract

Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I

wherein X, Y, B, R 2 , R 3 , R 4 , R 5 , R 6 and n have the meanings found herein.

First claim

What is claimed is:

1. A compound represented by Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
R A is selected from the group consisting of:

 and
R 6 is

2. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
7-[(1R,4S,5R)-4-Hydroxy-5-((E)-(S)-3-hydroxy-oct-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-ynoic acid methyl ester;
7-[(1R,4S,5R)-4-Hydroxy-5-((E)-(S)-3-hydroxy-oct-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-ynoic acid;
(Z)-7-[(1R,4S,5R)-4-Hydroxy-5-((E)-(S)-3-hydroxy-oct-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid;
(Z)-7-[(1R,4S,5R)-4-Hydroxy-5-((E)-(S)-3-hydroxy-oct-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid methyl ester;
or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and an pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and an pharmaceutically acceptable excipient.

Assignees

• Allergan Inc

Inventors

• Donde Yariv
• Nguyen Jeremiah H
• Kedzie Karen M
• Gil Daniel W
• Donello John E
• Im Wha-Bin

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• C07D409/08

  linked by a carbon chain containing alicyclic rings · CPC title

• C07D333/56 Primary

  Radicals substituted by oxygen atoms · CPC title

• C07D333/62

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring · CPC title